Estela Giménez

Estela Giménez

Auto-generated profile, based on publicly available information

Estela Giménez

Servicio de Microbiología, Hospital Clínico Universitario de Valencia, Valencia, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Journal of Clinical Virology
Verified
Journal Article
Closed access
EAEliseo Albert
Eliseo Albert
CSCarlos Solano
Carlos Solano
TPTania Pascual
Tania Pascual
ITIgnacio Torres
Ignacio Torres
LMLisa Macera
Lisa Macera
DNDavid Navarro
David Navarro

1 February 2013 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
MCMaría Ángeles Clari
María Ángeles Clari
DBDayana Bravo
Dayana Bravo
ECElisa Costa
Elisa Costa
BMBeatriz Muñoz-Cobo
Beatriz Muñoz-Cobo
CSCarlos Solano
Carlos Solano
DNDavid Navarro
David Navarro

1 May 2015 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MFM. Fernández-Ruiz
M. Fernández-Ruiz
ICI. Corrales
I. Corrales
MAM. Arias
M. Arias
JCJ. M. Campistol
J. M. Campistol
EGE. Giménez
E. Giménez
DNDavid Navarro
David Navarro
In this study, we assessed the association between single-nucleotide polymorphisms (SNPs) in seven candidate genes involved in orchestrating the immune response against cytomegalovirus (CMV) and the 12-month incidence of CMV infection in 315 CMV-seropositive kidney transplant (KT) recipients. Patients were managed either by antiviral prophylaxis or preemptive therapy. CMV infection occurred in 140 patients (44.4%), including 13 episodes of disease. After adjusting for various clinical covariates, patients harboring T-allele genotypes of interleukin-28B (IL28B) (rs12979860) SNP had lower incidence of CMV infection (adjusted hazard ratio [aHR]: 0.66; 95% confidence interval [CI]: 0.46–0.96; p-value = 0.029). In the analysis restricted to patients not receiving prophylaxis, carriers of the TT genotype of toll-like receptor 9 (TLR9) (rs5743836) SNP had lower incidence of infection (aHR: 0.61; 95% CI: 0.38–0.96; p-value = 0.035), whereas the GG genotype of dendritic cell-specific ICAM 3-grabbing nonintegrin (DC-SIGN) (rs735240) SNP exerted the opposite effect (aHR: 1.86; 95% CI: 1.18–2.94; p-value = 0.008). An independent association was found between the number of unfavorable SNP genotypes carried by the patient and the incidence of CMV infection. In conclusion, specific SNPs in IL28B, TLR9 and DC-SIGN genes may play a role in modulating the susceptibility to CMV infection in CMV-seropositive KT recipients.

1 April 2016 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
DNDavid Navarro
David Navarro
PAPaula Amat
Paula Amat
RCRafael de la Camara
Rafael de la Camara
JLJavier López
Javier López
LVLourdes Vázquez
Lourdes Vázquez
CSCarlos Solano
Carlos Solano
Background. Preemptive antiviral therapy for active cytomegalovirus (CMV) infection in allogeneic stem cell transplant recipients (Allo-SCT) results in overtreatment and a high rate of recurrences. Monitoring of CMV-specific T-cell immunity may help to individualize treatments and minimize these problems. Methods. We conducted a prospective, multicenter, matched comparison-group study to evaluate the efficacy and safety of a novel strategy that consisted of interrupting anti-CMV therapy upon CMV DNAemia clearance and concurrent detection of phosphoprotein 65/immediate-early-1-specific interferon-γ-producing CD8+ T cells at levels of >1 cell/µL (within 30 days after the initiation of therapy). Immunological monitoring was performed on days +7, +14, +21, and +28 after treatment initiation. The primary endpoint was the cumulative incidence of recurrent DNAemia within 2 months after treatment cessation. Secondary endpoints were the length of antiviral treatment courses and the incidence of hematological toxicity. Results. Sixty-one patients were enrolled in the study group. Fifty-six patients were included in the matched-control group. Eleven patients (18%) fulfilled the criteria for antiviral treatment interruption. The cumulative incidence of recurrent CMV DNAemia was significantly lower (P = .02) in these patients than in patients in the comparative groups. Likewise, the length of antiviral treatment courses was significantly shorter in these patients than that in patients in the matched-control group (P = .003). No significant differences in the incidence of hematological toxicity was observed between the comparative groups. Conclusions. Our data support the clinical utility of combining immunological and virological monitoring for the management of CMV infection in a subset of Allo-SCT recipients.

30 October 2017 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
EAE Albert
E Albert
CSCarlos Solano
Carlos Solano
EGE Giménez
E Giménez
Daniele FocosiDaniele Focosi
Daniele Focosi
APA Pérez
A Pérez
DND Navarro
D Navarro

7 December 2015 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
CSC Solano
C Solano
EGE Giménez
E Giménez
JSJose Luis Pinana Sanchez
Jose Luis Pinana Sanchez
VVVíctor Vinuesa
Víctor Vinuesa
SPS Poujois
S Poujois
DND Navarro
D Navarro